The reaction specificity of various monoclonal antibodies against cultured cell lines derived from human leukemias and malignant lymphomas
Tobinai, K.; Hirose, M.; Minato, K.; Shimoyama, M.
Nihon Ketsueki Gakkai Zasshi Journal of Japan Haematological Society 45(5): 897-906
1982
ISSN/ISBN: 0001-5806 PMID: 7158252 Document Number: 189212
The specificity of 12 monoclonal antibodies was assessed by indirect immunofluorescence assay using 25 cultured cell lines derived from various human hemopoietic tumor cells. Reactivities of these 12 monoclonal antibodies were highly specific. Titer of the antibody was different among these cell lines. Titration of each monoclonal antibody requires the use of several cultured cell lines to determine an appropriate concentration for clinical use. Anti-Leu-1 and 10.2 (anti-human Lyt-2) reacted with all T-cell lines of various differentiation stage. Anti-Leu-1 and 10.2 are considered to react with pan T-cell antigen (so-called human T lymphocyte antigen). The 9.6 (anti-human Lyt-3) is considered to react with E, and they are considered to belong to the same differentiation stage as normal cortical thymocytes. Anti-T monoclonal antibodies designated as OKT-series are very useful for analysis of the differentiation of T-cell malignancies. J5, which had the same reaction specificity as CALLA, reacted with cultured cell lines derived from common All, C/T hybrid type ALL, pre-B ALL and Burkitt's lymphoma. J5 is considered a specific marker of lymphoid malignancies derived from lymphoid stem cells, some of pre-T cells, pre-B cells and some of immature B-cells. Anti-B1 is considered to be reactive with J5-positive common ALL, immature B-cell malignancy and mature B-cell malignancy, but unreactive with immunoblast and plasma cell malignancy. OKI1 showed almost the same reaction pattern as the heteroantiserum vs. Ia-like antigen. OKM1 and anti-Mol were considered to react with a differentiation antigen of myelomonocytoid cell lineage. The monoclonal antibodies specific for certain differentiation antigen will be highly useful to elucidate the cellular origin, differentiation stage and subset identification of human hemopoietic tumor cells.